Timeline
2019
2020
- Langen Junior Science Award
- WHO Declares Pandemic
- Paul Ehrlich and Ludwig Darmstaedter Prize
- Supply Bottleneck for Pneumococcal Vaccines
- Blood Donation Remains Possible
- Convalescent Plasma: First Clinical Trial
- COVID-19 Vaccines: First Clinical Trial
- Marketing Authorisation of Gene Therapy
- COVID-19 Vaccines: Second Clinical Trial Approved
- German Presidency of the EU Council
- COVID-19 Vaccines: Two Clinical Trials Approved
- Another Clinical Trial Approved
- Start of Two Rolling Review Procedures
- Allergen Products: European Standards
- Allergen Product: First European Marketing Authorisation
- COVID-19 Peptide Vaccine: First Clinical Trial
- COVID-19 Vaccine: Third Rolling Review Procedure
- Validation of COVID-19 Rapid Tests
- First Marketing Authorisation of a COVID-19 Vaccine
- SafeVac App Available
The pandemic leads to a significant increase in demand for pneumococcal vaccines. Via its supply bottleneck management system, the Paul-Ehrlich-Institut identifies the shortages of these vaccines. The official declaration of a supply shortage leads, in accordance with Section 79 of the Medicinal Products Act, to an exceptional authorisation enabling the import of the shortfall in vaccine doses. From 3 April 2020 onwards, additional doses of the pneumococcal vaccine Pneumovax 23 imported from Japan are available, as well as imported doses of Prevenar 13 from 28 April 2020.